Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Next Previous
Trial Profile

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Cardiovascular disorders; Myocardial infarction; Obesity; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT
  • Sponsors Novo Nordisk

Most Recent Events

  • 22 Jun 2026 According to the Novo Nordisk Media Release, based on data form OASIS trial programme and the SELECT trial, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain long-term weight reduction.
  • 28 Apr 2026 According to a Novo Nordisk media release, data from this study will be presented at the European Congress on Obesity, 12-15 May in Istanbul, Turkey.
  • 01 Apr 2026 According to Novo Nordisk media release, NICE made this recommendation in Final Draft Guidance (FDG) and Technology Appraisal Guidance (TAG) is expected by the end of April 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top